Dermatology

© Getty Images

Artax announces first patient dosed in psoriasis treatment trial

By Isabel Cameron

Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.

(Image: Getty/solarseven)

Novartis joins longitudinal study for RWD

By Maggie Lynch

Novartis Pharma AG partners with Target PharmaSolutions to support its global longitudinal observational study designed to generate real-world clinical data.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All